[An open clinical trial of cortexin in treatment of brain ischemia].
OBJECTIVE
to study cortexin efficacy in treatment of cognitive and affective disorders in brain ischemia (BI) comorbid to arterial hypertension and/or atherosclerosis.


METHODS
The results of the all-Russian screening of cortexin efficacy "Cognitive and affective disorders during treatment brain ischemia with cortexin" conducted in 50 000 patients with BI in 70 Russian cities in 2013 were used for an analysis. All patients received cortexin in dose 10 mg/day during 10 days. Patients were examined before treatment and 11 and 30 days after the beginning of treatment. We analyzed treatment results for 500 patients with BI, stage II, mean age 63,7 ± 10,23 years. Treatment efficacy was assessed using 5-score scale of subjective and objective neurological symptoms, the Five words test, the Schulte test, MMSE, Hamilton anxiety scale and a brief version of the Geriatric depression scale.


CONCLUSIONS
A decrease or complete regression of focal neurological symptoms, positive changes in indicators of cognitive impairment, normalization of emotional status and decrease in depression level were noted during the treatment.
V V
VV
Mashin
L A
LA
Belova
O I
OI
Chaplanova
A F
AF
Khusnullina
A M
AM
Manasian
D000368:Aged; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D012720:Severity of Illness Index
D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; C056590:cortexin